Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 Next >
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
From Can-Fite BioPharma Ltd.
Via GlobeNewswire
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Present at the Emerging Growth Conference on July 13, 2023
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback